Understanding the Biology of Joint Degeneration
For decades, patients with chronic joint pain faced a difficult choice: manage symptoms indefinitely with medications that mask the problem, or undergo invasive surgery that carries significant risk and requires months of rehabilitation. Regenerative biologics are offering a third path that supports the body's natural processes rather than simply suppressing symptoms.
Joints degrade for a variety of reasons — repetitive stress, acute injury, autoimmune conditions, and the natural aging process among them. What these causes share is a common mechanism: the breakdown of cartilage, tendon, and connective tissue faster than the body can repair it. Conventional treatments — NSAIDs, corticosteroid injections, physical therapy — address the inflammatory response but do nothing to restore the underlying structural integrity of the joint.
What Happens During a Stem Cell Injection
This is where regenerative biologics change the equation. Mesenchymal stem cells, when introduced to a site of tissue damage, release a cascade of paracrine signals — chemical messengers that engage the body's own natural processes, modulate inflammation, and support the production of new cartilage and connective tissue. Individual results may vary.
At CellRX, every injection protocol begins with a comprehensive consultation. Our Medical Director reviews imaging, assesses the degree of joint damage, and determines the appropriate dosing — typically between 1 CC and 10 CC of concentrated biologics, depending on the severity of the condition and the patient's goals.
The procedure itself takes under 60 minutes. Using ultrasound or fluoroscopic guidance when indicated, the biologics are delivered precisely to the site of damage. There is no general anesthesia, no hospital stay, and no surgical incision. The vast majority of patients return to normal activities the same day.
What the Research Shows
What distinguishes CellRX from other providers is the provenance of the biologics. Our Medical Director serves simultaneously as the Medical Director of our stem cell source company — meaning every vial has been under direct physician oversight from the moment of ethical procurement through the moment of administration. The biologics are never diluted, never replicated, and always sourced from healthy, consented local births.
The clinical literature on mesenchymal stem cell therapy for joint conditions has grown substantially over the past decade. Studies published in peer-reviewed journals including the American Journal of Sports Medicine and Stem Cells Translational Medicine have documented meaningful improvements in pain scores, functional outcomes, and cartilage volume in patients with knee osteoarthritis, rotator cuff injuries, and hip degeneration following stem cell injection.
Who Is a Candidate?
It is important to note that regenerative medicine is a rapidly evolving field, and outcomes vary based on the quality of the biologic product, the precision of delivery, and the individual patient's biology. At CellRX, we are transparent about what the evidence supports and what remains under investigation — because an informed patient is an empowered patient.
Stem cell injection therapy is most appropriate for patients who have exhausted conservative treatments without achieving satisfactory relief, and who are not yet at the stage of joint damage that makes surgery unavoidable. It is also an excellent option for patients who are surgical candidates but wish to explore alternatives before committing to an invasive procedure.
The Timeline of Results
Common conditions for which patients seek regenerative consultation include knee osteoarthritis, hip osteoarthritis, rotator cuff tears and tendinopathy, Achilles tendinopathy, plantar fasciitis, and degenerative disc disease. The consultation process will determine whether your specific condition and degree of damage make you a strong candidate for this approach.
Regenerative support operates at the cellular level, which means the timeline of results is different from conventional treatments. Many patients report initial improvements in pain and inflammation within the first two to four weeks. Continued biological support unfolds over three to six months. Individual results may vary. These statements have not been evaluated by the FDA.